There's more than one way to build a biotech

 

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and… 
289 clip(s)
Loading playlist

As biotech companies continue to navigate a challenging funding environment, Axiom Biosciences is taking an unconventional approach to raising capital and developing new therapies.

The company is pursuing a public listing in Hong Kong, with ambitions to eventually list on the Nasdaq. Meanwhile, it's developing several drug delivery platforms, including a stem cell therapy approach that doesn't rely on genetic modification.

In this episode of "The Top Line," Fierce Biotech's Marissa Russo speaks with Axiom founder and CEO Remo Moomiaie-Qajar about the company's financing strategy, its approach to drug development and what's next for its clinical pipeline.

To learn more about the topics in this episode: